イノベーションの推進と国民皆保険制度の維持
日本の将来を考えるにあたり、国民の日々の安心が守られ、必要な革新的医薬品が国民に遅滞なく届くよう、国民皆保険制度を維持しつつ、戦略産業の観点からもイノベーションを推進し、国力を高めることが重要です。医薬品に焦点を当て、日本における課題と議論を整理し、薬価制度、薬事制度といった具体的な取り組みについて考察します。
日本の将来を考えるにあたり、国民の日々の安心が守られ、必要な革新的医薬品が国民に遅滞なく届くよう、国民皆保険制度を維持しつつ、戦略産業の観点からもイノベーションを推進し、国力を高めることが重要です。医薬品に焦点を当て、日本における課題と議論を整理し、薬価制度、薬事制度といった具体的な取り組みについて考察します。
不確実な時代だからこそ、世の中の変化と流れを読み解き、他社に先駆けて有効な手を打つことが競争優位性の構築につながります。本書では、序章で不確実性に対応するためのシナリオプランニングの手法を紹介し、第1章以降でBCGが重要と考える10の潮流について変化の本質と経営へのインパクトを考察し2023年にとるべきアクションを提示します。
さまざまな医療機関への経営改善支援の経験を基に、医療の質と生産性をともに高めるための考え方と実践的手法について解説します。経営層と現場が一体となった経営改善活動の推進に向け明日から取り組める打ち手が盛り込まれています。
Dr. Alexandra Bause explains how today’s reactive approach provides sick care, not health care—and how biopharma strives to change that.
By leveraging innovative business models and partnerships, biopharma companies could reach patients in low- and middle-income countries at no extra cost.
The IRA provisions concerning the pricing of drugs for Medicare patients are creating new economic realities for health care players.
Manufacturing costs are rising rapidly, with no end in sight. Leaders that balance the various tradeoffs can remain competitive over the long run.
Implementing GenAI is not easy in an industry with a complex value chain and intensive regulatory oversight. Companies will wrestle with both choice and complexity.
Chief Digital and Technology Officer Lidia Fonseca explains how Pfizer is leveraging digital and data across the value chain and the biggest wins so far.
Hudson discusses the company’s commitment to reaching net zero emissions by 2045.
Francis discusses the role that Teva’s people are playing in the execution of the company’s new growth strategy.
Chief Commercial Officer Everett Cunningham describes Exact Sciences’ efforts to boost awareness of this deadly disease.
The technology is evolving rapidly, but five simple steps can help providers capitalize on GenAI to improve performance, reduce costs, and enhance the experience for patients and staff.
To thrive during turbulent economic times, health systems can learn from the aviation industry, which embraced novel diversification approaches to maintain revenue stability and improve profitability.
While digital, data, and AI have extraordinary potential to revolutionize our global health care systems, they have yet to deliver a transformative impact. How can the public and private sectors accelerate progress?
The latest technologies hold tremendous promise for health care, but they also pose significant challenges. Not all organizations are prepared to take advantage of the tech trends.
Most environmental waste generated by the health care sector comes from medtech products. For a sector focused on improving quality of life, reducing waste and greenhouse gases is imperative.
To realize the promise and potential for GenAI, medtech executives must make swift and targeted efforts.
Medtech management teams face an unfamiliar list of questions. The players that can successfully navigate the challenging terrain will be the winners of the 2020s.
The technology has a range of uses in medtech, and the main challenge is knowing how and where to start. Here are 60 ways to generate quick wins.
BCG conducted a study of more than 70 organizations—including philanthropies, multilateral development banks, government agencies, nongovernmental organizations, private sector actors, and others—to understand how key stakeholders are approaching the climate-health challenge.
Too often is it taken for granted that the environment is a massive determinant of human well-being. Putting health at the center of our climate discussions is critical.
The biopharma industry faces demands for more action to address health inequities. We provide a guide and tools to help companies integrate equity across the product lifecycle.
What has worked, what can be improved, and what needs to be reimagined so that we are better prepared for the next pandemic and better able to improve health in the world’s poorest nations?